What is T-knife?
Founded in 2018, T-knife operates at the intersection of advanced immunology and precision medicine. As a spin-off from the Max-Delbruck Center for Molecular Medicine and supported by the Charité University Hospital, the company specializes in the discovery and engineering of T cell receptors (TCRs) designed to target and eliminate cancer cells with high specificity. T-knife's market position is defined by its commitment to transforming the standard of care through sophisticated, science-led therapeutic interventions. By focusing on the fundamental mechanisms of the immune system, the company aims to provide durable, effective treatments for patients suffering from complex malignancies, thereby establishing itself as a key player in the European biotechnology ecosystem.
How much funding has T-knife raised?
T-knife has raised a total of $187.2M across 2 funding rounds:
Series A
$77.2M
Series B
$110M
Series A (2020): $77.2M with participation from RA Capital Management, Versant Ventures, Andera Partners, and Boehringer Ingelheim Venture Fund
Series B (2021): $110M led by RA Capital Management, Qatar Investment Authority, Versant Ventures, Caas Capital Management, Casdin Capital, Life Sciences Partners, Fidelity, and Sixty Degree Capital
Key Investors in T-knife
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing an internal think tank to support scientific and clinical data analysis.
Versant Ventures
A global venture capital firm that partners with exceptional entrepreneurs to build innovative biotechnology companies, backed by extensive scientific expertise and a strong track record of IPOs.
Qatar Investment Authority
A sovereign wealth fund specializing in foreign and domestic investment across diverse asset classes, including private equity and alternative assets to drive long-term value.
What's next for T-knife?
With the recent influx of capital, T-knife is strategically positioned to advance its lead programs through the rigorous stages of clinical development. The company's roadmap emphasizes the expansion of its proprietary TCR platform, which is expected to yield a broader portfolio of candidates targeting diverse oncological indications. Furthermore, the firm is likely to focus on strengthening its internal scientific capabilities and fostering strategic partnerships to enhance its global reach. As T-knife moves into this next phase of growth, the focus will remain on achieving clinical proof-of-concept, which will be instrumental in determining the long-term commercial viability of its therapeutic pipeline and its potential to disrupt the current oncology market.
See full T-knife company page
